INTRODUCING CG1.4
CG1.4 is designed to treat various inflammatory and autoimmune diseases by inhibiting the production of TNFα and other proinflammatory cytokines at their source. This differs from current biologics, which attempt to completely block only TNFα after its production. However TNFα has several positive effects in the body which are also blocked by biologic drugs. By addressing inflammation more comprehensively, but not completely blocking the effects of TNFα, CG1.4 provides similar health benefits to biologics yet eliminates the potential for a number of serious side effects, including certain cancers and disruption of neurological homeostasis. As an orally administered medication, CG1.4 offers greater convenience with significantly reduced risks and a lower cost compared to injectable biologics.
RADIX'S FIRST POLYMOLECULAR DRUG CANDIDATE
Driven by a Mission
Driven by a passion for innovation, Radix BioScience is pioneering a new era in healthcare. Our mission is to empower patients by developing groundbreaking solutions that address the complexities of chronic diseases without the burden of harmful side effects.
Shaping the Future of Healthcare
Learn more
Partners in Innovation
Seize the opportunity to invest in a company at the forefront of botanical drug development. Join us on our mission to revolutionize healthcare.
Invest in a brighter future
Join us
